Other

Novo Nordisk to buy RNA technology firm

Denmark's Novo Nordisk, the world's leading insulin maker, said Thursday it will buy US-based Dicerna Pharmaceuticals, a developer of RNA interference technology which targets genes that cause disease.

Oncology & Cancer

Combining BMI with body shape better predictor of cancer risk

New research being presented at The European Congress on Obesity (ECO) held online this year, suggests that a measure of body shape should be used alongside body mass index (BMI) to help determine the risk of obesity-related ...

page 4 from 40